CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Intracerebral Infusion of Autologous Cerebral Spinal Fluiddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03540134
NCT03540134N/ACompleted
CompareCT.gov

Convection Enhanced Delivery of Autologous Cerebral Spinal Fluid Improves MRI Visualizations of Basal Ganglion Nuclei During Deep Brain Stimulation Surgery

Jeff Elias, MD·interventional·Posted May 30, 2018·Updated Apr 8, 2021

In Brief

A clinical study evaluating Intracerebral Infusion of Autologous Cerebral Spinal Fluid for Parkinson Disease. Completed, enrolled 4 participants across 1 site.

Detailed Summary

This study will evaluate safety foremost but also the distribution and initial effectiveness of infusion-enhanced, MRI-guided DBS for patients with medication-refractory, Parkinson's disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 30, 2018
Enrollment StartFeb 13, 2018
Primary CompletionDec 18, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.1 years ago

Interventions

Intracerebral Infusion of Autologous Cerebral Spinal Fluiddevice

Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring